MedTrace Logo

A Study of the Effectiveness and Safety of Ramipril in the Treatment of Hypertension in Children and Adolescents

NCT00389519 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 422

Last updated 2012-06-11

Study results available
· View outcomes & findings →

Summary

The primary purpose of this study is to evaluate the blood pressure lowering effects of ramipril, an FDA-approved drug for the treatment of hypertension in adults, in children and adolescents aged 6 to 16 years with hypertension.

Conditions

Interventions

DRUG

ramipril

once a day oral ramipril capsules given for 4 weeks

DRUG

placebo

once a day oral placebo capsule for 4 weeks

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
6 Years
Max Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2007-11-30
Completion
2007-11-30

Countries

  • United States
  • Argentina
  • Chile
  • Colombia
  • India
  • Poland
  • South Africa
  • Turkey (Türkiye)
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00389519 on ClinicalTrials.gov